Focus: Praxis Precision Medicines is a Boston-based biotech specialist focused on genetic neuroscience treatments, with a deep pipeline in rare neurological disorders and seizure indications. The company operates at mid-cap scale with 25 active job openings and is actively advancing multiple Phase 2/3 programs.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Stable — net +1 jobs in 30d
17 added, 16 removed. Backfill posture.
Attractive for early-to-mid career professionals seeking deep neuroscience/rare disease expertise and clinical momentum, but regulatory headwinds and pre-revenue status demand risk tolerance.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Praxis Precision Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Praxis Precision Medicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
symbol__ Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast CNN
Praxis bets on skin patch for essential tremor drug - Stock Titan
Praxis bets on skin patch for essential tremor drug Stock Titan
Praxis Precision Medicines and Remagine Labs Announce - GlobeNewswire
Praxis Precision Medicines and Remagine Labs Announce GlobeNewswire
FDA hits Praxis with 3-month delay for epilepsy drug verdict - BioSpace
FDA hits Praxis with 3-month delay for epilepsy drug verdict BioSpace
Praxis faces FDA delay, analysts point finger at agency layoffs - Fierce Biotech
Praxis faces FDA delay, analysts point finger at agency layoffs Fierce Biotech
Praxis Precision Medicines (PRAX) Receives a Buy from TD Cowen - The Globe and Mail
Praxis Precision Medicines (PRAX) Receives a Buy from TD Cowen The Globe and Mail
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo